Stimulant Management in ADHD Patients with Alcohol Relapse

Rationale for Discontinuation

The American Academy of Child and Adolescent Psychiatry recommends that stimulants should be discontinued in ADHD patients who continue to relapse and use alcohol, as ongoing alcohol use represents a significant risk that outweighs the potential benefits of continued stimulant therapy 1, 2
A "black box" warning in methylphenidate, dextroamphetamine, and amphetamine package inserts explicitly warns against using these medications in patients with a history of recent stimulant drug abuse or dependence 1, 2

Atomoxetine does not carry the same abuse potential as stimulants 3
Clonidine and guanfacine may be preferable first-line options in patients with comorbid substance use disorders 4

Regular assessment of ADHD symptoms, substance use patterns, and overall functioning should continue after stimulant discontinuation 4
Consider implementing specific substance use monitoring, including regular alcohol screening tests, Cognitive Behavioral Therapy focused on substance use, and medications specifically for alcohol dependence such as naltrexone or acamprosate 4

Stimulants may be reconsidered only after documented sustained sobriety (minimum 3-6 months) and implementation of appropriate substance use disorder treatment 2, 4

Continuing stimulants despite evidence of ongoing alcohol use increases risk of diversion and misuse 5, 6
Not implementing adequate monitoring for both ADHD symptoms and substance use 4
Overlooking the need for comprehensive substance use treatment alongside ADHD management 4

Patients with ADHD and alcohol use disorder require more intensive monitoring than those without substance use issues 2
Non-pharmacological interventions for ADHD should be emphasized when stimulants are discontinued 4